PO.CL01.08 · 临床研究
血浆全外显子组测序(pWES)与组织全外显子组测序(tWES)的一致性评估:非小细胞肺癌(NSCLC)的一项初步研究
Concordance evaluation of plasma whole-exome sequencing (pWES) and tissue whole-exome sequencing (tWES): A pilot study in non-small cell lung cancer (NSCLC)
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:通过pWES进行的循环肿瘤DNA(ctDNA)分析为以微创方式全面表征肿瘤来源的改变以及纵向监测肿瘤分子演变提供了可能。在此,我们开展了一项初步研究,以评估在NSCLC中一种内容增强的pWES检测相比tWES的分析性能。
方法:使用PredicineWES+检测(WES加600基因增强panel;汇度上海医学科技有限公司,中国)分析从商业获取的I-IV期NSCLC患者血浆样本中分离的游离DNA。拷贝数负荷评分(cnbScore;一种全基因组拷贝数异常的定量测量,作为肿瘤分数[TF]的替代指标)来源于低深度血浆全基因组测序(pWGS)。pWES TF基于非同义体细胞突变(单核苷酸变异[SNV]+插入缺失)的最大突变等位基因分数。采用Jaccard指数(JI)、Spearman相关性(ρ)和Wilcoxon秩和检验来量化pWES与tWES各项指标之间的一致性和差异。
结果:40个样本中有39个通过低深度pWGS进行评估(II-III期占80%)。高TF(cnbScore ≥5.6)与晚期肿瘤和鳞状细胞癌(SCC)组织学相关。选择了30个样本(cnbScore最高的25个和最低的5个)进行pWES。pWES TF与pWGS cnbScore显著相关(ρ = 0.64;P < 0.001)。在通过pWES评估的30个样本中,14个为ctDNA阳性(cnbScore ≥5.6),并被纳入与tWES的一致性分析。腺癌和SCC特异性驱动突变在pWES与配对tWES之间高度一致(JI = 0.72)。NSCLC主导的吸烟相关突变特征可通过pWES识别,并与tWES相关(ρ = 0.58)。pWES与tWES之间观察到相当程度的突变检出一致性(中位JI = 0.47)。血液肿瘤突变负荷(TMB)与组织TMB高度相关(ρ = 0.69)。与非增强外显子区域相比,具有更高测序深度的增强区域在pWES与tWES之间具有数值上更好的TMB相关性(ρ = 0.81对比0.64)和SNV一致性(中位JI = 0.80对比0.44)。pWES与tWES之间观察到不一致的拷贝数变异结果,可能是由于低ctDNA TF和组织中的拷贝数增加。
结论:通过pWES获得的ctDNA肿瘤负荷指标与低深度pWGS相关,并显示出与NSCLC肿瘤分期和组织学亚型的关联。pWES可行地表征了NSCLC中的TMB和SNV,尤其是在ctDNA阳性样本和增强的600基因WES panel中,表明其在治疗期间纵向肿瘤分析和监测方面的潜在效用。
查看英文原文 English abstract
Background: Circulating tumor DNA (ctDNA) analysis by pWES offers the possibility for comprehensive characterization of tumor-derived alterations and longitudinal monitoring of tumor molecular evolution in a minimally invasive manner. Here, we conducted a pilot study to evaluate the analytical performance of a pWES assay with boosted content compared with tWES in NSCLC.
Methods: Cell-free DNA isolated from commercially-acquired plasma samples of patients with stage I-IV NSCLC were analyzed using the PredicineWES+ assay (WES plus a boosted 600-gene panel; Huidu Shanghai Medical Sciences Ltd, China). The copy number burden score (cnbScore; a quantitative measure of genome-wide copy number abnormality as a proxy for tumor fraction [TF]) was derived from low-pass plasma whole-genome sequencing (pWGS). pWES TF was based on the maximum mutation allele fraction of nonsynonymous somatic mutations (single nucleotide variants [SNVs] + indels). Jaccard Index (JI), Spearman correlation (ρ), and Wilcoxon rank-sum test were applied to quantify concordance and differences across measures between pWES and tWES.
Results: 39/40 samples were evaluated by low-pass pWGS (stage II-III, 80%). A high TF (cnbScore ≥5.6) was associated with late-stage tumors and squamous cell carcinoma (SCC) histology. Thirty samples (25 highest and 5 lowest cnbScore samples) were selected for pWES. pWES TF was significantly correlated with pWGS cnbScore (ρ = 0.64; P < 0.001). Of 30 samples evaluated by pWES, 14 samples were ctDNA-positive (cnbScore ≥5.6) and were included in concordance analyses with tWES. Adenocarcinoma- and SCC-specific driver mutations were highly concordant between pWES and matched tWES (JI = 0.72). NSCLC-dominant smoking-associated mutational signature was identifiable by pWES and was correlated with tWES (ρ = 0.58). Considerable concordance of mutation calling was observed between pWES and tWES (median JI = 0.47). Blood tumor mutational burden (TMB) was highly correlated with tissue TMB (ρ = 0.69). Compared with nonboosted exome region, boosted region with higher sequencing depth had numerically better TMB correlation (ρ = 0.81 vs 0.64) and SNV concordance (median JI = 0.80 vs 0.44) between pWES and tWES. Disconcordant copy number variant results were observed between pWES and tWES, possibly due to low ctDNA TF and copy number gain in tissue.
Conclusions: ctDNA tumor burden metrics by pWES correlated with low-pass pWGS and showed association with tumor stage and histologic subtype of NSCLC. pWES feasibly characterized TMB and SNV in NSCLC especially in ctDNA-positive samples and in the boosted 600-gene WES panel, indicating potential utility for longitudinal tumor profiling and monitoring during treatment.
利益披露 Disclosure
B. Dong,
Merck & Co., Inc. Employment, Stock.
Z. Wang,
Merck & Co., Inc. Employment, Stock.
C. E. Peña,
Merck & Co., Inc. Employment, Stock.
X. Liu,
Merck & Co., Inc. Employment, Stock.
G. Zeng,
Merck & Co., Inc. Employment, Stock.